In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically 'undruggable' protein, in just two months. This ...
In Canada, colorectal cancer is projected to be the fourth most commonly diagnosed cancer in 2024 (excluding non-melanoma skin cancers), according to the Canadian Cancer Society.